A new study in BMC, examines the net benefits of the rotavirus vaccine (RV) in Uganda. When analyzing costs averted due to RV, the authors found that Uganda saved approximately $57 million ($7 per capita) in diarrhea-related expenses between 2018 and 2021, excluding productivity losses from mortality. The return on investment (ROI) from RV was estimated to be $1.48 for every dollar invested. When mortality costs were included, the net benefits shot up to $3 billion in economic cost ($385 per capita) and a ROI of $78 for each dollar invested. This paper highlights the critical role of rotavirus vaccine in reducing the impact of diarrheal diseases and associated costs in Uganda.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.